Vesin P
Postgrad Med J. 1975 Aug;51(598):545-8. doi: 10.1136/pgmj.51.598.545.
The author first reviews, on the basis of personal and literature data, the main changes in three major parameters of potassium metabolism: serum potassium; daily urinary output of potassium; exchangeable potassium (Ke) at the three stages of the course of liver cirrhosis. The action of K-sparing diuretics (spironolactone, triamterene, amiloride) on these parameters is analysed. Although the introduction of these diuretics in our therapeutic armamentarium has resulted in a major advance, i.e. the quasi-total elimination of iatrogenic hypokalaemia and hypokalaemia-induced portacaval encephalopathy in the cirrhotic, the limits of their action on K metabolism are underlined: they may moderately enhance urinary K output; following cessation of their administration, a ‘rebound’ in urinary K output may be noted. Finally, Ke may still continue to decrease during their administration, indicating an aggravation of the underlying disease. It was also found that a rise in serum K and/or Ke during amiloride administration did not prevent the elevation of plasma renin activity usually induced by volume and/or Na depletion.
作者首先根据个人及文献资料,回顾了肝硬化病程三个阶段钾代谢的三个主要参数的主要变化:血清钾、每日尿钾排出量、可交换钾(Ke)。分析了保钾利尿剂(螺内酯、氨苯蝶啶、阿米洛利)对这些参数的作用。尽管这些利尿剂引入我们的治疗手段后取得了重大进展,即几乎完全消除了肝硬化患者医源性低钾血症及低钾血症所致的门腔静脉性脑病,但仍强调了它们在钾代谢方面作用的局限性:它们可能会适度增加尿钾排出量;停药后,尿钾排出量可能会出现“反弹”。最后,在用药期间Ke仍可能继续下降,表明基础疾病在加重。还发现,在使用阿米洛利期间血清钾和/或Ke升高,并不能阻止通常由容量和/或钠缺失引起的血浆肾素活性升高。